<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Victoria Hendrick, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H87621144"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>For bipolar patients who plan to or do become pregnant, maintenance pharmacotherapy is often indicated to delay or prevent mood episodes [<a href="#rid1">1,2</a>]. Onset of bipolar disorder in women typically occurs during childbearing years [<a href="#rid3">3</a>], and most patients are thus at risk for recurrences during pregnancy [<a href="#rid1">1</a>].</p><p>This topic reviews indications for preconception and prenatal maintenance pharmacotherapy in female bipolar patients. Preconception and prenatal maintenance treatment, the teratogenic and postnatal risks of medications used for bipolar disorder, and contraception and preconception counseling for female bipolar patients are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16971.html" rel="external">"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15701.html" rel="external">"Bipolar disorder in women: Contraception and preconception assessment and counseling"</a>.)</p><p></p><p class="headingAnchor" id="H87620884"><span class="h1">DEFINITION OF BIPOLAR DISORDER</span><span class="headingEndMark"> — </span>Bipolar disorder is a mood disorder that is characterized by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 1</a>), hypomania  (<a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 2</a>), and major depression  (<a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">table 3</a>) [<a href="#rid4">4</a>]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H87620142"><span class="h1">FACTORS INVOLVED IN THE DECISION TO USE MAINTENANCE PHARMACOTHERAPY</span><span class="headingEndMark"> — </span>The decision to use preconception and prenatal maintenance pharmacotherapy involves many factors, including the [<a href="#rid1">1,5-14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient’s lifetime course of illness:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Number of mood episodes</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of episodes that included psychotic features (delusions and hallucinations) and/or suicide attempts</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comorbid psychopathology (eg, anxiety or substance use disorders) and general medical illnesses</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Occupational and interpersonal functioning</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Duration of euthymia during pharmacotherapy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Time to relapse following discontinuation of pharmacotherapy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Time to recovery following resumption of pharmacotherapy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Efficacy of specific medications during gravid and nongravid periods</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>General risk of mood episodes during pregnancy (see  <a class="medical medical_review" href="/z/d/html/15701.html" rel="external">"Bipolar disorder in women: Contraception and preconception assessment and counseling", section on 'Risk of maternal mood episodes'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reproductive safety data for medications, including (see  <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Miscarriage</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Major and minor structural malformations</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fetal growth restriction</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neonatal toxicity and withdrawal</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adverse postnatal developmental effects upon behavior, cognition, and emotional regulation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential consequences of maternal mood episodes during pregnancy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suicidal behavior</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Impulsive, risky behavior</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Substance abuse</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malnutrition</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poor adherence with prenatal care</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low birth weight</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adverse postnatal developmental effects</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diminished mother-infant bonding</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Disrupted family functioning</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient’s preferences and values regarding:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent mood episodes compared with teratogenicity. As an example, one patient may be more concerned about remaining asymptomatic and working to support herself and other children, while another patient with more financial resources may place more value upon avoiding fetal toxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The possibility of terminating a pregnancy if there is evidence of a malformation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Support and monitoring that is available</p><p></p><p class="headingAnchor" id="H87620149"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Preconception and prenatal maintenance treatment are often indicated for female bipolar patients, based upon the high risk of recurrent mood episodes in prospective observational studies, particularly in patients who discontinued pharmacotherapy [<a href="#rid2">2,15</a>]. However, for patients with a mild lifetime course of illness, it is reasonable to try to forego medications during pregnancy [<a href="#rid1">1,16</a>]. The risk of recurrent mood episodes is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15701.html" rel="external">"Bipolar disorder in women: Contraception and preconception assessment and counseling", section on 'Risk of maternal mood episodes'</a>.)</p><p class="headingAnchor" id="H87620156"><span class="h2">Mild lifetime course of illness</span><span class="headingEndMark"> — </span>A mild lifetime course of illness is characterized by [<a href="#rid1">1,17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent euthymia (eg, ≥2 years) between mood episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Mood episodes that resolve completely within weeks of initiating treatment</p><p class="bulletIndent1"><span class="glyph">●</span>No history of suicide attempts or psychotic features (delusions or hallucinations)</p><p></p><p>For female bipolar patients with a mild lifetime course of illness who are planning a pregnancy, we suggest maintenance pharmacotherapy during conception and pregnancy to prevent mood episodes, based upon prospective observational studies that found untreated pregnant patients were at increased risk of recurrent mood episodes [<a href="#rid2">2,15</a>], as well as our clinical experience and that of several authorities [<a href="#rid1">1,16-18</a>]. However, patients with good social support may reasonably attempt to forego pharmacotherapy during the first trimester (when the risk of malformations is greatest), during the third trimester to avoid postnatal effects of drugs, or during the entire pregnancy to minimize any drug-related effects [<a href="#rid1">1,16</a>].</p><p>For bipolar patients who decline maintenance pharmacotherapy during the first trimester and remain euthymic, we suggest restarting pharmacotherapy during the second trimester, when organogenesis is essentially completed. A reasonable alternative is for patients to wait until they develop prodromal symptoms before resuming pharmacotherapy; however, subsyndromal symptoms are associated with an increased risk of full-blown relapses [<a href="#rid19">19</a>].</p><p>For female bipolar patients who are receiving maintenance pharmacotherapy and decide to stop it in anticipation of a pregnancy, we suggest that clinicians:</p><p class="bulletIndent1"><span class="glyph">●</span>Taper and discontinue pharmacotherapy over a period of two to four weeks. The risk of recurrence may be greater if medications are stopped more abruptly [<a href="#rid1">1,2,20</a>]. (See  <a class="medical medical_review" href="/z/d/html/15701.html" rel="external">"Bipolar disorder in women: Contraception and preconception assessment and counseling", section on 'Relapse after discontinuing pharmacotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Taper the medications by the same amount for each dose decrease; as an example, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> 1200 mg per day is decreased by 300 mg per day, every five to seven days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitor patients every one to four weeks, depending upon the number and severity of mood symptoms [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Observe patients during a short medication-free trial (eg, two to three months) before patients attempt to conceive, to gauge whether patients will remain euthymic during pregnancy without medications [<a href="#rid16">16,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Educate patients about methods to increase their likelihood of conception (eg, home ovulation detection kits and intercourse every other day during the week ovulation is expected), to minimize the time off of medications [<a href="#rid21">21</a>].</p><p></p><p>If bipolar symptoms recur during the medication taper, the medication is generally titrated back up to the full dose used initially to maintain euthymia. If a full-blown mood episode develops despite resuming the initial medication dose and does not improve within four to eight weeks, we suggest switching treatment. The treatment of bipolar mood episodes in patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p>For bipolar patients who are medication free during the entire pregnancy, we suggest restarting maintenance pharmacotherapy after delivery to prevent postpartum mood episodes, based upon the high risk of recurrent postpartum mood episodes [<a href="#rid1">1,21</a>]. (See  <a class="medical medical_review" href="/z/d/html/83170.html" rel="external">"Bipolar disorder in postpartum women: Treatment", section on 'Euthymic patients'</a>.) </p><p class="headingAnchor" id="H87620163"><span class="h2">Moderate to severe lifetime course of illness</span><span class="headingEndMark"> — </span>A moderate to severe course of illness is exemplified by one or more of the following [<a href="#rid1">1,17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Frequent mood episodes (eg, ≥1 episode every two years) despite adequate maintenance treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Mood episodes resistant to treatment (eg, require months to years to resolve completely)</p><p class="bulletIndent1"><span class="glyph">●</span>History of suicide attempts or psychotic features (delusions and hallucinations)</p><p></p><p>For female bipolar patients with a moderate to severe lifetime course of illness who are planning a pregnancy, we suggest preconception and prenatal maintenance pharmacotherapy to prevent mood episodes, based upon prospective observational studies that found untreated pregnant patients were at increased risk of recurrent mood episodes [<a href="#rid2">2,15</a>], as well as our clinical experience and that of several authorities [<a href="#rid1">1,16-18,21,22</a>].</p><p class="headingAnchor" id="H4018944794"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115361.html" rel="external">"Society guideline links: Bipolar disorder"</a>.)</p><p class="headingAnchor" id="H13499864"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (See  <a class="medical medical_basics" href="/z/d/html/15348.html" rel="external">"Patient education: Bipolar disorder (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (See  <a class="medical medical_patient" href="/z/d/html/4869.html" rel="external">"Patient education: Bipolar disorder (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>.)</p><p></p><p>These educational materials can be used as part of psychoeducational psychotherapy. (See  <a class="medical medical_review" href="/z/d/html/14666.html" rel="external">"Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Group psychoeducation'</a>.)</p><p>The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled "Bipolar Disorder," which is available online at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fbipolar-disorder&amp;token=c9TXCEotcdMcarRyXBEnhwgIEx3THC4PwSF2z%2FRKFh%2B8HmGSkeqm5bDBx4bOcfNh0qAPwOVFAtZ6twY6hM0vtq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=82834" target="_blank">website</a> or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.</p><p>More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).</p><p>The Depression and Bipolar Support Alliance (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=82834" target="_blank">the website</a> or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.</p><p>The National Alliance on Mental Illness (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=82834" target="_blank">the website</a> or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.</p><p class="headingAnchor" id="H87621380"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar disorder is a mood disorder that is characterized by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 1</a>), hypomania  (<a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 2</a>), and major depression  (<a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">table 3</a>). (See <a class="local">'Definition of bipolar disorder'</a> above and  <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The decision to use maintenance pharmacotherapy for female bipolar patients planning a pregnancy involves many factors, including the following (see <a class="local">'Factors involved in the decision to use maintenance pharmacotherapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patient’s lifetime course of illness</p><p class="bulletIndent2"><span class="glyph">•</span>General risk of maternal mood episodes during pregnancy</p><p class="bulletIndent2"><span class="glyph">•</span>Reproductive safety of medications</p><p class="bulletIndent2"><span class="glyph">•</span>Potential consequences of maternal mood episodes during pregnancy</p><p class="bulletIndent2"><span class="glyph">•</span>Patient’s preferences and values</p><p class="bulletIndent2"><span class="glyph">•</span>Support and monitoring that is available</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar disorder is a highly recurrent illness, particularly in pregnant patients who forego pharmacotherapy. For patients who are planning a pregnancy, maintenance pharmacotherapy is generally indicated. However, for patients with a mild lifetime course of illness, it is reasonable to try to avoid medications during pregnancy. (See <a class="local">'Indications'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.</a></li><li><a class="nounderline abstract_t">Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007; 164:1817.</a></li><li><a class="nounderline abstract_t">Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64:543.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Wisner KL, Zarin DA, Holmboe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000; 157:1933.</a></li><li class="breakAll">Stewart DE, Vigod SN, Stotland NL. Obstetrics and gynecology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Inc, Washington, DC 2011. p.797.</li><li><a class="nounderline abstract_t">Kurki T, Hiilesmaa V, Raitasalo R, et al. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95:487.</a></li><li><a class="nounderline abstract_t">Alder J, Fink N, Bitzer J, et al. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med 2007; 20:189.</a></li><li><a class="nounderline abstract_t">Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 2006; 29:445.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001. Reaffirmed Obstet Gynecol 2018; 131:185. Reaffirmed 2020.</a></li><li class="breakAll">National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38, 2006. http://www.nice.org.uk/ (Accessed on March 07, 2012).</li><li class="breakAll">Newport DJ, Fernandez SV, Juric S, Stowe ZN. Psychopharmacology during pregnancy and lactation. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.1373.</li><li><a class="nounderline abstract_t">Lee HC, Lin HC. Maternal bipolar disorder increased low birthweight and preterm births: a nationwide population-based study. J Affect Disord 2010; 121:100.</a></li><li><a class="nounderline abstract_t">Bauer MS. Bipolar Disorder. Ann Intern Med 2022; 175:ITC97.</a></li><li><a class="nounderline abstract_t">Newport DJ, Stowe ZN, Viguera AC, et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008; 10:432.</a></li><li><a class="nounderline abstract_t">Sharma V, Sharma P, Sharma S. Managing bipolar disorder during pregnancy and the postpartum period: a critical review of current practice. Expert Rev Neurother 2020; 20:373.</a></li><li><a class="nounderline abstract_t">Cohen LS. Treatment of bipolar disorder during pregnancy. J Clin Psychiatry 2007; 68 Suppl 9:4.</a></li><li><a class="nounderline abstract_t">Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord 2004; 6:2.</a></li><li><a class="nounderline abstract_t">Keller MB, Lavori PW, Kane JM, et al. Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Arch Gen Psychiatry 1992; 49:371.</a></li><li class="breakAll">Burt VK, Stein K. Treatment of women. In: The American Psychiatric Publishing Textbook of Psychiatry, Fifth Edition, Hales RE, Yodofsky SC, Gabbard GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.1489.</li><li><a class="nounderline abstract_t">Cohen LS, Wang B, Nonacs R, et al. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 2010; 33:273.</a></li><li><a class="nounderline abstract_t">Burt VK, Bernstein C, Rosenstein WS, Altshuler LL. Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications. Am J Psychiatry 2010; 167:892.</a></li></ol></div><div id="topicVersionRevision">Topic 82834 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15056503" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of bipolar disorder during pregnancy and the postpartum period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056236" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485606" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485606" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11097953" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk-benefit decision making for treatment of depression during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11097953" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk-benefit decision making for treatment of depression during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10725477" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Depression and anxiety in early pregnancy and risk for preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437220" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17138297" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prenatal depression effects on the fetus and newborn: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378767" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378767" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378767" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501914" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Maternal bipolar disorder increased low birthweight and preterm births: a nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35816713" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Bipolar Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18402631" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lamotrigine in bipolar disorder: efficacy during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32172610" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Managing bipolar disorder during pregnancy and the postpartum period: a critical review of current practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17764378" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment of bipolar disorder during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996136" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Special considerations in treating bipolar disorder in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1586272" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1586272" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385337" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment of mood disorders during pregnancy and postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693466" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
